What is this study trying to find out about neurologic disorders?

This study is evaluating whether stem cells taken from a person's own bone marrow and given through the blood and nose can improve neurologic function in various neurologic diseases. Researchers want to learn how this treatment affects conditions like stroke, traumatic brain injury, and neurodegenerative diseases. The sponsor, MD Stem Cells, is conducting this research to add knowledge about these stem cell treatments.

Who may be eligible for this neurologic disorders clinical trial?

Adults aged 18 and older with documented nerve system damage unlikely to improve with standard care may be eligible. Participants should be stable on current treatments and at least 6 months past disease onset. Both men and women can join if medically stable and able to consent. Please review eligibility criteria for more details.

Is there any cost to participate in this neurologic disorders clinical trial?

Study-related care, including the stem cell procedure and all trial visits, is provided at no cost. Personal travel and other expenses may vary and are not guaranteed to be covered. Participants should plan accordingly for any costs related to attending study visits.

Actively Recruiting

Phase Not Applicable

Age: 18Years +

All Genders

ID02795052

Neurologic Bone Marrow Derived Stem Cell Treatment Study

Led by MD Stem Cells · Updated on 2025-06-06

500

Participants Needed

Research Sites

52 weeks

Total Duration

AI-Summary

What this Trial Is About

This research aims to evaluate the use of autologous bone marrow derived stem cells BMSC delivered intravenously and intranasally to improve neurologic function in patients with various neurologic conditions. The study focuses on patients with documented functional damage to the central or peripheral nervous system that is unlikely to improve with current standard care. The investigators seek to add to existing knowledge by studying the effects of BMSC in conditions such as stroke, traumatic brain injury, Parkinsons disease, Alzheimers disease, and other neurodegenerative disorders. The treatment involves collecting the participants own bone marrow to isolate stem cells, which are then given through an intravenous infusion and applied topically to the lower third of the nasal passages on both sides. This intranasal approach targets the trigeminal nerve pathways that may help the stem cells enter the brain and central nervous system. Participants receive this combined intravenous and intranasal BMSC treatment during the study period. Participants will undergo neurologic function assessments at baseline and at 1, 3, 6, and 12 months after treatment to measure changes. They will be monitored through neurologic exams and evaluations to track potential improvements and safety. Medical stability and clearance by a primary care physician are required before treatment, and follow-up visits with neurologists are part of the study to observe outcomes over one year.

CONDITIONS

Brief Title

Neurologic Stem Cell Treatment Study

Who Can Participate

Age: 18Years +

All Genders

Eligibility Criteria

You may qualify if you...

Have documented functional damage to the central or peripheral nervous system unlikely to improve with current standard care
Be at least 6 months post-onset of the neurologic disease
Be stable on any current medical or surgical treatment for the condition
Be assessed by investigators as having potential for improvement with stem cell treatment and low risk of harm
Be 18 years or older and capable of providing informed consent
Be medically stable and cleared by a primary care physician to undergo the procedure

You will not qualify if you...

Must be capable of undergoing thorough neurologic examination and evaluation
Must be willing and able to attend follow-up neurologic exams as required
Must be capable of providing informed consent
Must be assessed as having low risk of harm from stem cell collection and treatment
Must be medically stable and not at significant health risk from the procedure
Women of childbearing age must not be pregnant and should avoid pregnancy for 3 months after treatment

Research Team

Steven Levy, MD

Not the Right Trial for You?

Explore thousands of other clinical trials that might be a better match.
Sign up to get personalized trial recommendations delivered to your inbox.

Already have an account? Log in here